SCHEMBL1656313

SCHEMBL1656313

NC1=Nc2cc(C(=O)N3CCCC3)ccc2C=C(C(=O)O)C1

nearest known ligand 0.69

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 20/20 0.69
TLR7 Q9NYK1 14/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1094511 0.91 TLR8 (0.71) TLR8TLR7
SCHEMBL1238138 0.90 TLR8 (0.69) TLR8TLR7
SCHEMBL10325171 0.84 TLR8 (0.60) TLR8TLR7
SCHEMBL22790540 0.83 TLR8 (0.72) TLR8TLR7
SCHEMBL1802374 0.83 TLR8 (0.73) TLR8TLR7
SCHEMBL1237666 0.82 TLR8 (0.72) TLR8TLR7
SCHEMBL19642416 0.82 TLR8 (1.00) TLR8TLR7
SCHEMBL27950487 0.80 TLR8 (0.50) TLR8TLR7
SCHEMBL10324863 0.79 TLR8 (0.53) TLR8TLR7
SCHEMBL7511336 0.78 TLR8 (0.54) TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160331758-A1 TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE VENTIRX PHARMACEUTICALS, INC. 2016-11-17 US claimed
US-20130018042-A1 Toll-Like Receptor Agonist Formulations and Their Use VENTIRX PHARMACEUTICALS, INC. 2013-01-17 US claimed
JP-2011529916-A 2011-12-15 JP claimed
EP-2322510-A2 8-substituted benzoazepines as toll-like receptor modulators Array Biopharma, Inc. (US) 2011-05-18 EP claimed
EP-2313111-A1 TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE Ventirx Pharmaceuticals, Inc. (US) 2011-04-27 EP claimed
WO-2010014913-A1 TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE VENTIRX PHARMACEUTICALS, INC. (US) 2010-02-04 WO claimed
US-20100029585-A1 TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE VENTIRX PHARMACEUTICALS, INC. 2010-02-04 US claimed
US-20080234251-A1 8-Substituted Benzoazepines as Toll-Like Receptor Modulators ARRAY BIOPHARMA INC. (US) 2008-09-25 US claimed
EP-1940797-A2 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS Array Biopharma, Inc. (US) 2008-07-09 EP claimed
WO-2007024612-A2 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS ARRAY BIOPHARMA INC. (US) 2007-03-01 WO claimed
US-20160331758-A1 TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE VENTIRX PHARMACEUTICALS, INC. 2016-11-17 US disclosed
EP-3081558-A1 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS Array Biopharma, Inc. (US) 2016-10-19 EP disclosed
US-9216192-B2 Toll-like receptor agonist formulations and their use VENTIRX PHARMACEUTICALS, INC. (US) 2015-12-22 US disclosed
EP-2313111-B1 TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE VENTIRX PHARMACEUTICALS INC (US) 2013-09-04 EP disclosed
US-20130018042-A1 Toll-Like Receptor Agonist Formulations and Their Use VENTIRX PHARMACEUTICALS, INC. 2013-01-17 US disclosed
WO-2010014913-A1 TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE VENTIRX PHARMACEUTICALS, INC. (US) 2010-02-04 WO disclosed
US-20100029585-A1 TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE VENTIRX PHARMACEUTICALS, INC. 2010-02-04 US disclosed
US-20080234251-A1 8-Substituted Benzoazepines as Toll-Like Receptor Modulators ARRAY BIOPHARMA INC. (US) 2008-09-25 US disclosed
EP-1940797-A2 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS Array Biopharma, Inc. (US) 2008-07-09 EP disclosed
WO-2007024612-A2 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS ARRAY BIOPHARMA INC. (US) 2007-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018042-A1 Toll-Like Receptor Agonist Formulations and Their Use TLR8, TLR7, TLR1 TLR8 1/4885TLR7 2/4885
US-20080234251-A1 8-Substituted Benzoazepines as Toll-Like Receptor Modulators TLR8, TLR7, TLR9 TLR8 1/4885TLR7 2/4885
US-20160331758-A1 TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE TLR8, TLR7, TLR1 TLR8 1/4885TLR7 2/4885
US-20100029585-A1 TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE TLR8, TLR7, TLR1 TLR8 1/4885TLR7 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.